Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/57610
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRolan, P.en
dc.contributor.authorHutchinson, M.en
dc.contributor.authorJohnson, K.en
dc.date.issued2009en
dc.identifier.citationExpert Opinion on Pharmacotherapy, 2009; 10(17):2897-2904en
dc.identifier.issn1465-6566en
dc.identifier.issn1744-7666en
dc.identifier.urihttp://hdl.handle.net/2440/57610-
dc.description© 2009 Informa UK Ltden
dc.description.abstractIbudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-inflammatory activity in both the peripheral immune system and in the CNS via glial cell attenuation. This CNS-directed anti-inflammatory activity is of potential use in the treatment of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by decreasing opioid tolerance, withdrawal and reinforcement. Its suitable pharmacokinetics and generally good tolerability make it a promising potential treatment for these conditions.en
dc.description.statementofresponsibilityP. Rolan, M.R. Hutchinson & K.W. Johnsonen
dc.language.isoenen
dc.publisherAshley Publications Ltd.en
dc.subjectglia; ibudilast; multiple sclerosis; neuropathic pain; primingen
dc.titleIbudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological diseaseen
dc.typeJournal articleen
dc.identifier.rmid0020094448en
dc.identifier.doi10.1517/14656560903426189en
dc.identifier.pubid36325-
pubs.library.collectionPharmacology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.